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RESUMO
Introdução: O ustekinumab é um anticorpo monoclonal dirigido contra a subunidade p40 presente nas IL-12 e 23. A evidência da 
sua eficácia e segurança em ensaios clínicos é amplamente conhecida. No entanto a evidência da sua utilização na prática clínica é 
relativamente limitada na população Portuguesa. O objetivo deste trabalho é relatar a experiência de dois serviços de dermatologia 
Portugueses no tratamento da psoríase moderada a grave com ustekinumab.
Material e Métodos: Foram avaliados os dados clínicos, demográficos, e de resposta terapêutica ao ustekinumab em 116 doentes 
com psoríase tratados entre novembro de 2009 e dezembro de 2015. 
Resultados: Observou-se uma resposta terapêutica ≥ PASI75 em 67,2%, 85,3%, 89,6% e 88,7% dos doentes às semanas 4, 12, 24 
e 52, respetivamente. O ustekinumab foi descontinuado em sete doentes (três por falências primárias, três por falências secundárias 
e um por evento adverso). Não foram observados eventos cardiovasculares nem reativações de infecções prévias (tuberculose, 
hepatite B). Em nove doentes foi utilizado em simultâneo metotrexato, e em catorze foi necessário otimizar a dose de ustekinumab. 
Não foram observados efeitos colaterais nestes grupos. A resposta terapêutica foi superior nos doentes naïve a terapêuticas biológicas 
comparativamente com os doentes não-naïve. Observou-se uma tendência para resposta clínica inferior nos doentes com peso entre 
90 – 100 kg.
Discussão e Conclusão: Este estudo confirma a segurança e eficácia de ustekinumab no tratamento da psoríase moderada a grave 
em doentes da prática clínica real, sustenta a eficácia mesmo nos doentes previamente expostos a terapêutica biológica e aponta para 
a possível necessidade de ajustar a dose a partir dos 90 kg.
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ABSTRACT
Introduction: Ustekinumab is a monoclonal antibody directed against the p40 subunit common to both IL-12 and IL-23 cytokines. 
Although the evidence of ustekinumab efficacy and safety in clinical trials is extensively recognized, data on its use in clinical practice is 
limited. Our objective is to report on the real-life experience of two Portuguese dermatology departments with ustekinumab in patients 
with moderate to severe psoriasis, and to identify the clinical characteristics associated with a weaker clinical response.  
Material and Methods: Clinical, demographic, and therapeutic response data was retrospectively collected in 116 patients with 
moderate to severe psoriasis treated with ustekinumab between November 2009 and December 2015. 
Results: A PASI75 therapeutic response was observed in 67.2%, 85.3%, 89.6% and 88.7% of patients at weeks 4, 12, 24 and 52, 
respectively. Ustekinumab was discontinued in seven patients (three due to primary failure, three due to secondary treatment failure, 
and one due to adverse events). Neither cardiovascular events nor cases of reactivation of previous infections (tuberculosis, hepatitis 
B) were observed during follow-up. In nine patients methotrexate was used as adjuvant therapy, and fourteen patients required 
ustekinumab dosage optimization. No side effects were observed in the two latter groups. The therapeutic response was higher in 
patients naïve to biologic therapies as compared to non-naïve patients.
Discussion and Conclusion: A trend towards lower clinical response was observed in patients weighing between 90-100 kg, and 
dosage optimization in this group of patients may be of value prior to considering biologic switch.
Keywords: Biological Products/therapeutic use; Psoriasis/drug therapy; Ustekinumab/therapeutic use
INTRODUCTION
 Ustekinumab is a monoclonal antibody targeting the p40 
subunit common to the IL-12 and 23 cytokines,1 whose ther-
apeutic efficacy and safety are well documented in clinical 
trial populations.2,3
 Body weight affects clearance capacity and volume of 
distribution of numerous drugs.4 Specifically, in the case of 
ustekinumab, the patient’s weight exerts a pronounced in-
fluence on pharmacokinetics by altering the drug clearance 
and distribution volume.5 This is the rationale for the recom-
mendation of different dosing regimens of ustekinumab in 
patients below and above a defined weight threshold (45 
mg or 90 mg every 12 weeks in patients weighting < 100 kg 
and ≥ 100 kg, respectively).4,6
 As compared with clinical trials, the real-life practice with 
ustekinumab showed that a proportion of patients is either 
unresponsive or loses efficacy with the aforementioned 
dosing regimen.6-9 This scenario often leads to ustekinum-
ab dosage increase, interval adjustments, introduction of 
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adjuvant therapy, or biologic switch.6,10-14 Additionally, previ-
ous experience in clinical trials and real-life practice showed 
that, in certain patient groups the loss of therapeutic re-
sponse can be a transitory phenomenon, and the intensi-
fication of the drug regimen may allow the maintenance of 
the initial biologic, as such avoiding the ‘exhaustion’ of other 
therapeutic choices.15
 Analysis of data derived from real-life practice that would 
enable the identification of clinical characteristics associat-
ed with a weaker clinical response, would, in some patients, 
allow considering alternative dosing regimens rather than 
just switching biologics.
 The objective of our study is to identify the clinical char-
acteristics associated with a weaker clinical response in pa-
tients with psoriasis treated with ustekinumab.
MATERIAL AND METHODS
 The real-life experience of two Portuguese dermatology 
departments with ustekinumab in the treatment of moder-
ate to severe psoriasis is hereby presented through a ret-
rospective observational patient cohort. Clinical data of 116 
patients treated with ustekinumab in Centro Hospitalar do 
Porto (Porto) and Clinica Laser de Belém (Lisboa) between 
November 2009 and December 2015 were collected. De-
mographic data, history of psoriasis (age of onset, family 
history), presence of psoriatic arthritis (PsA), baseline Pso-
riasis Area Severity Index (PASI), along with previous thera-
pies, comorbidities, serious adverse events (SAE), and 
therapeutic response were assessed. 
RESULTS
Cohort clinical and demographic characteristics 
 A total of 116 patients with moderate-to-severe psoriasis 
(50 female and 66 male patients) treated with ustekinumab 
were retrospectively analysed. The mean age of onset of 
psoriasis in our cohort was 26 years (± 15.2, range 2 - 71), 
while mean disease duration was 21.8 years (± 12.8, range 
4 - 62). Twenty-four (20.7%) patients had a diagnosis of PsA 
in our cohort. Regarding disease severity, the mean base-
line PASI was 13.2 (± 5.1, range 8 - 27.6). Mean weight of 
our cohort of patients was 78.3 kg (± 17.2, range 46 - 118), 
and mean body mass index (BMI) was 27.3 (± 5.1, range 
17.9 - 46.9).
 The prevalence of cardiovascular risk factors was ana-
lysed: hypertension was present in 30.2% patients, dyslipi-
daemia in 30.2%, and diabetes in 11.2% patients. Obesity 
(BMI > 30) and overweight (BMI 25 - 30) were identified in 
23.3% and 39.7% of our patient cohort, respectively. Re-
Figure 1 – Clinical response to ustekinumab [PASI75 responders (%)] in naïve and non-naïve patients. Efficacy data analysed with 
intention to treat: non-responder imputation (ITT-NRI). 
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garding smoking status, 32.8% of patients were current 
smokers, while 21.6% had smoked in the past.
 Pre-treatment infectious screening identified 52 cases 
of latent tuberculosis and two patients with serologic tests 
compatible with past hepatitis B viral infection (HBcAb posi-
tive; HBsAg negative; HBV DNA negative). 
 Regarding previous therapies – phototherapy, cyclo-
sporine, methotrexate and acitretin were previously used in 
37.9%, 27.6%, 23.3% and 25% patients, respectively. The 
majority of our group of patients (93 patients; 80.2%), was 
naïve to biologic treatments. Among the 23 patients (19.8%) 
who had prior biologic experience, there was a mean wash-
out period of 5.5 weeks. Infliximab, adalimumab and etaner-
cept were previously used in 21.7%, 30.4% and 47.8% of 
patients, respectively. Three patients experienced more 
than one previous biologic. 
Therapeutic response analysis 
 The therapeutic response (defined as PASI75 or more) 
at week 4, 12, 24, 52 was recorded, as was the total treat-
ment duration. Primary endpoint analysis was made at 
week 12, 24 and 52. Missing data from the main cohort 
were handled using intention-to-treat non-responder impu-
tation (ITT-NRI) analysis, using SPSS. 
 Regarding response to treatment, PASI75 response 
was achieved by 67.2% (78/116), 85.3% (99/116), 89.6% 
(104/116) and 88.7% (103/116) at week 4, 12, 24 and 52, 
respectively. In our patient cohort, the maximum total group 
follow-up was week 60, at which response rate remained 
sustained (102/116; 87.9%).
 Naïve patients achieved superior clinical response as 
compared to non-naïve patients, and that was statistically 
significant at week 24 (p = 0.045) (Fig. 1). This finding goes 
in line with observations reported by other groups.8,16 In fact, 
the clinical response to a drug switch in patients with bio-
logic experience is generally lower than in naïve patients, 
not only for ustekinumab, but also for other therapeutic 
classes.15
 Regarding treatment interruption, ustekinumab was 
discontinued in seven patients [3 due to primary failure, 3 
due to secondary treatment failure, and one due to adverse 
event (facial palsy)]. 
 Considering patients that have escaped standard treat-
ment, in 13 dosing intervals were temporarily reduced (8/8 
weeks) due to loss of efficacy, and one patient required a 
dose escalation due to weight gain and worsening of the 
disease. 
 Concerning adjuvant therapy, methotrexate was used in 
one patient at the beginning of treatment (concomitant diag-
nosis of PsA), and as add-on therapy in eight patients due to 
loss of clinical response. Five out of eight of these patients 
later regained PASI75 response. The use of methotrexate 
is reported to help maintain clinical response, not only due 
to the drug’s adjuvant immunosuppressive action but also 
owing to a collateral effect of inhibition of production of anti-
drug antibodies.11 No adverse events were reported in this 
group of patients, but further long-term studies are needed 
to establish the long-term effects of this immunomodulatory 
association. Until then, a case-to-case scenario evaluation 
needs to be assessed for every individual patient. 
 Considering the treatment response according to the 
patients’ weight (Fig. 2), a tendency to inferior clinical re-
sponse was observed in patients weighting 90 - 100 kg. 
When patients under the standard dose of ustekinumab 
were analysed, this difference was statistically significant at 
week 24 (p = 0.035). These observations are in accordance 
with previous reports, which seem to point to a probable 
need of up-dosing in these patients, as the proximity to the 
‘weight-adjustment’ threshold makes clinical response to 45 
mg of ustekinumab less efficacious.10 
 Seventy-four patients had a follow-up duration of at 
least 120 weeks. When analysing a cohort subset that 
Figure 2 – Number of patients achieving PASI75 response (%), stratified by weight categories, < 90 kg, 90 – 100 kg and ≥ 100 kg. (A): total 
cohort of patients (total n: 116); (B): patients under standard dosage of ustekinumab (total n: 102). 
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includes these long-term follow up patients along with pa-
tients that discontinued treatment during our study period, 
the observed PASI75 response was 80.7% (63/78), 84.6% 
(66/78), 87.2% (68/78), and 94.9% (74/78) at week 12, 24, 
52 and 120. These long-term follow-up PASI75 values un-
derline that the initial response to treatment represents the 
primary predictor of ultimate therapeutic success in a given 
patient, and that the continuation of treatment makes failure 
less probable (excluding factors such as development of 
side effects or weight increases that lessen drug efficacy).
 As far as adverse events, one patient developed facial 
palsy during treatment (week 180), and even though this 
event was not proven to be associated to the drug, the 
possible relation led to ustekinumab suspension. No major 
adverse cardiovascular events (MACE) were reported dur-
ing the treatment period. Regarding screening of infectious 
diseases, adequate prophylaxis was implemented and no 
reactivations were detected during follow-up.
DISCUSSION AND CONCLUSION
 Our experience with the long-term use of ustekinumab 
in a heterogeneous group of real-life patients demonstrated 
an excellent safety profile and absence of major adverse 
events. Despite a high prevalence of cardiometabolic and 
infectious comorbidities in our cohort, it is important to note 
the absence of related SAEs during follow-up.
 Upon secondary failure during treatment of moderate 
to severe psoriasis with biologics, there is uncertainty con-
cerning the decision to either switch to another agent or to 
intensify the primary biological (by altering drug dose or the 
frequency of administration).6 Decision-making has to take 
into account not only the expected therapeutic response, 
but also the economic impact of these options. On the one 
hand, the cost of introducing a new biological will require 
taking into consideration not only the new induction phase 
but also the costs that are inherent to additional medical vis-
its and diagnostic tests.15 On the other hand, the cost of the 
therapy intensification will depend on the amount and dura-
tion of the latter.15 The suspension and initiation of biologic 
therapy should be judicious insofar as patients experienced 
in prior biologics appear to have suboptimal therapeutic re-
sponse rates, as observed in our patient group.
 We report a sustained long-term PASI75 response and 
treatment persistence in the majority of our group of pa-
tients. An inferior therapeutic response was observed in 
non-naïve patients and patients in the 90 - 100 kg weight 
interval, which goes in line with previous reports. This find-
ing seemingly indicates that the proximity to the upper limit 
of the weight threshold is associated with a significant re-
duction of therapeutic response rates. The TRANSIT study 
demonstrated the benefit of dose escalation from 45 to 90 
mg in patients weighting < 100 kg who did not reach PASI75 
at week 28.17 Despite the low number of patients in each of 
the weight categories in our cohort of patients, it seems that 
the dosage-adjustment threshold may have been set too 
high. The significance of weight in treatment efficacy em-
phasizes the importance of regular weight measurements in 
medical appointments in these patients, as previously sug-
gested.10 The usefulness in clinical practice of the aware-
ness and recognition of this group of patients may be note-
worthy for implementation of weight reduction plans (dietary 
change, exercise prescription) along with both temporary 
dose escalation and interval shortening, prior to taking into 
consideration drug switching due to treatment failure. 
 Weight loss is recommended in all psoriatic patients 
who are overweight or obese.17 This measure is essential 
not only to reduce cardiovascular risk burden, but also to 
optimize clinical response to several therapies.19
 In conclusion, ustekinumab is an effective and safe ther-
apeutic agent in patients with moderate to severe psoriasis, 
and our experience has furthermore shown the ability of re-
capturing clinical response via temporary dose adjustments 
as well as a safe drug interaction profile with adjuvant ther-
apy such as methotrexate.
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